title: Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.
abstract: Very small size proteoliposomes (VSSP) constitute a complex of very small size proteoliposomes that includes proteins, lipids, CpG and gangliosides tumor-associated that provides a potential target for cancer immunotherapy. This compound has been described to stimulate the humoral and cellular response, dendritic cells (DC) activation and differentiation of T-helper cells, specially, in immunocompromised patients with cancer status. This work deals with the stimulating capacity of the VSSP to reach a humoral response when they are used as a component in a peptidic vaccine based on the gonadotrophin releasing hormone (GnRH). This study was carried out in male Copenhagen rats, which were immunized with 750μg of the GnRH mimetic peptide (GnRHm1-TT) with or without the VSSP. The mixtures were always emulsified with the oil adjuvant Montanide ISA 51. The anti GnRH seroconversion analysis revealed that the group immunized with the peptide GnRHm1-TT/VSSP developed a strong anti GnRH seroconversion. These antibody levels proved to be significant superior to those reached by the use of the GnRHm1-TT peptide solely emulsified in Montanide. Post-mortem analysis on the Testosterone ablation target organs (prostate and testicles) yielded a sudden decrease in their size and weight in respect to the control group. On the other hand, the group submitted to the use of GnRHm1-TT/VSSP, showed a significant difference in the reduction of these target organs in comparison with the group only immunized with GnRHm1-TT adjuvated in Montanide ISA 51. These values turned to be of p=0.023 and p=0.009 in the prostate and testicles respectively. These findings foreground the VSSP as a useful immunopotentiator to be used as part of a GnRH based vaccine to treat prostate cancer.
authors.affiliation: Centro de Ingeniería Genética y Biotecnología Camagüey, Cuba. franklin.fuentes@cigb.edu.cu
authors.forename: Franklin Fuentes
authors.initials: FF
authors.lastname: Aguilar
authors.forename: Jesús Junco
authors.initials: JJ
authors.lastname: Barranco
authors.forename: Eddy Bover
authors.initials: EB
authors.lastname: Fuentes
authors.forename: Lesvia Calzada
authors.initials: LC
authors.lastname: Aguilera
authors.forename: Yovisleydis Lopez
authors.initials: YL
authors.lastname: Sáez
authors.forename: María Dolores Castro
authors.initials: MD
authors.lastname: Santana
authors.forename: Eulogio Pimentel
authors.initials: EP
authors.lastname: Vázquez
authors.forename: Roberto Basulto
authors.initials: RB
authors.lastname: Baker
authors.forename: Osvaldo Reyes
authors.initials: OR
authors.lastname: Acosta
authors.forename: Hilda Garay
authors.initials: HG
authors.lastname: Pérez
authors.forename: Gerardo Guillén
authors.initials: GG
authors.lastname: Nieto
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000906:Antibodies / Q000097:blood; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000276:immunology*; D008297:Male; D008353:Mannitol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D009829:Oleic Acids / Q000008:administration & dosage*; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D011510:Proteolipids / Q000008:administration & dosage*; D051381:Rats
chemical_list: D000276:Adjuvants, Immunologic; D000906:Antibodies; D019496:Cancer Vaccines; D009829:Oleic Acids; D011510:Proteolipids; C477385:montanide ISA 51; C020485:proteoliposomes; D007987:Gonadotropin-Releasing Hormone; D008353:Mannitol